Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Inclusion Criteria: * Subjects must have measurable disease OR must be evaluable for disease progression * Age \>/= 18 years. * Postmenopausal women * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. * Histologically or cytologically confirmed ER and/or PgR positive carcinoma of the breast with unresectable, locally advanced and/or metastatic disease * Subjects must have received prior hormonal therapy for the treatment of breast cancer (anastrozole, letrozole, or tamoxifen) * Adequate hematologic, hepatic, and renal function Exclusion Criteria: * Prior use of exemestane or pazopanib * Premenopausal women * Any ongoing toxicity from prior anti-cancer therapy that is \>Grade 1 and/or that is progressing in severity. * Prior therapy with a VEGF inhibitor. * Use of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of investigational product. * Evidence of recurrence or active disease from prior malignancy. * Clinically significant gastrointestinal abnormalities that may increase the risk for GI bleeding or affect the absorption of the investigational product(s). * Presence of uncontrolled infection. * History of any major cardiovascular conditions within the past 6 months: * Poorly controlled hypertension * History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. * Prior major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer * Evidence of active bleeding or bleeding tendency.